You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

mass. movers

Curis stock plunges as drug trial stalls

Curis must provide more safety data to resume testing. Above, a cancer patient gets radiation treatment.

San Antonio Express-News via AP

Curis must provide more safety data to resume testing. Above, a cancer patient gets radiation treatment.

Continue reading below

Curis Inc., which is developing cancer therapies, plunged after the Lexington company unveiled quarterly results and an FDA action. Revenue swelled to $7.2 million, from less than $0.6 million a year earlier, and the net loss shrank by nearly half to $1.9 million. But Curis’s cancer drug CUDC-427 was put on partial hold by the FDA — negating any chance of enrolling new patients in a phase 1 study. A patient died of liver failure a month after the end of CUDC-427 treatment.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com